Better Value & Growth: RMD, BDX Lead Abbott Laboratories Stock
RMD, BDX are Abbott Laboratories’s peers in Health Care Equipment industry that have:
1) Lower valuation (P/OpInc) compared to Abbott Laboratories stock
2) But higher revenue and operating income growth
This disconnect between valuation and performance could mean that you are better off buying RMD, BDX stocks vs. ABT stock
Portfolio beats stock-picking every time. Consider what could long-term performance for your portfolio be if you combined 10% commodities, 10% gold, and 2% crypto with equities.
- RMD, BDX Top Abbott Laboratories Stock on Price & Potential
- Better Value & Growth: RMD, BDX Lead Abbott Laboratories Stock
- Pay Less, Grow More: RMD, BDX Outshine Abbott Laboratories Stock
- Better Bet Than Abbott Laboratories Stock: Pay Less To Get More From RMD, BDX
- Better Bet Than Abbott Laboratories Stock: Pay Less To Get More From RMD, BDX
- Better Bet Than Abbott Laboratories Stock: Pay Less To Get More From RMD, BDX
Key Metrics Compared
| Metric | ABT | RMD | BDX |
|---|---|---|---|
| P/OpInc* | 28.9x | 20.6x | 18.6x |
| LTM OpInc Growth | 15.2% | 18.9% | 16.0% |
| 3Y Avg OpInc Growth | -3.2% | 20.3% | 8.1% |
| LTM Revenue Growth | 6.4% | 9.4% | 7.9% |
| 3Y Avg Revenue Growth | -0.6% | 13.3% | 4.1% |
OpInc = Operating Income, P/OpInc = Price To Operating Income Ratio
But do these numbers tell the full story? Read Buy or Sell ABT Stock to see if Abbott Laboratories still has an edge that holds up under the hood. As a quick background, Abbott Laboratories (ABT) provides health care products across pharmaceuticals, diagnostics, nutrition, and medical devices, specializing in cardiovascular treatments including rhythm management, electrophysiology, and heart failure solutions.
This is just one approach to evaluate investments. Trefis High Quality Portfolio evaluates much more, and is designed to reduce stock-specific risk while giving upside exposure
Is The Mismatch In Stock Price Temporary
One way to check if Abbott Laboratories stock is expensive now versus the other tickers would be to see how these metrics compared across companies exactly a year ago. Specifically, if there has been a marked reversal in the trend for Abbott Laboratories in the last 12 months, then there is a chance that the current mismatch is likely to reverse. On the other hand, a persistent underperformance in revenue and operating income growth for Abbott Laboratories would reinforce the conclusion that the stock is expensive compared to its peers, but may not revert soon
Key Metrics Compared 1 Yr Prior
| Metric | ABT | RMD | BDX |
|---|---|---|---|
| P/OpInc* | 26.6x | 21.1x | 23.3x |
| LTM OpInc Growth | 15.9% | 21.9% | 9.8% |
| 3Y Avg OpInc Growth | -6.1% | 19.0% | 5.9% |
| LTM Revenue Growth | 5.9% | 9.8% | 5.8% |
| 3Y Avg Revenue Growth | -1.5% | 12.9% | 3.4% |
OpInc = Operating Income
Additional Metrics To Consider
| Metric | ABT | RMD | BDX |
|---|---|---|---|
| P/S | 5.3x | 7.6x | 2.3x |
| Market Cap (Current) | $ 223.0 Bil | $ 36.3 Bil | $ 55.1 Bil |
| LTM Revenue | $ 43.84 Bil | $ 5.26 Bil | $ 21.39 Bil |
| LTM Opinc | $ 7.71 Bil | $ 1.76 Bil | $ 2.96 Bil |
| LTM Op Margin | 17.6% | 33.5% | 13.8% |
OpInc = Operating Income
Alternate buying based on valuation, while attractive, needs to be evaluated carefully from multiple angles. Such multi-factor analysis is exactly how we construct Trefis portfolio strategies. If you want upside with a smoother ride than an individual stock, consider the High Quality portfolio, which has outperformed the its benchmark – a combination of S&P 500, Russell, and S&P midcap index.